Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company.
The business
Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study
Neurizon gains ethics approval for NUZ-001 oral liquid Phase 1 ALS study in Australia; trial slated to start Q3 2026 and finish Q4 2026.
Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial
Neurizon Therapeutics (ASX: NUZ) has successfully raised over $44 million AUD through a multi-pronged capital raise, securing funding to advance its lead drug candidate NUZ-001 through the **H
Neurizon Therapeutics confirms potential of NUZ-001 as platform therapy for ALS and Huntington’s disease
Clinical-stage biotechnology company Neurizon Therapeutics (ASX: NUZ) has continued its success in proving the versatility of lead drug candidate NUZ-001. New studies have confirmed NUZ-001’s potential to provide significant blood–brain barrier penetration. Rodent preclinical pharmacokinetic (PK) data have found that NUZ-001 and its major active metabolite NUZ-001 sulfone effectively cross the blood–brain barrier (BBB) and […]
Neurizon Therapeutics reports positive study results on human brain model by neuroprotective candidate NUZ-001
Neurizon Therapeutics (ASX: NUZ) has reported positive results from an independent study into the effects of neuroprotective candidate NUZ-001 on a 3D human brain model developed by Tessara Therapeutics. The results showed that NUZ-001 and NUZ-001 sulfone (the major active metabolite) exhibited strong safety characteristics in Tessara’s ArtiBrain model over a three-day period at doses […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.